BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Sells $529,250.00 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 25,000 shares of BioLife Solutions stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $21.17, for a total transaction of $529,250.00. Following the sale, the executive vice president now directly owns 302,046 shares in the company, valued at approximately $6,394,313.82. The trade was a 7.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

BioLife Solutions Trading Up 1.5 %

Shares of BLFS stock opened at $25.39 on Friday. BioLife Solutions, Inc. has a fifty-two week low of $11.91 and a fifty-two week high of $28.88. The company has a 50 day moving average price of $23.96 and a 200 day moving average price of $22.88. The stock has a market capitalization of $1.18 billion, a P/E ratio of -23.95 and a beta of 1.88. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78.

Institutional Trading of BioLife Solutions

A number of large investors have recently modified their holdings of BLFS. Mark Sheptoff Financial Planning LLC acquired a new position in BioLife Solutions during the 3rd quarter worth $28,000. 1620 Investment Advisors Inc. purchased a new stake in shares of BioLife Solutions during the second quarter worth approximately $35,000. Isthmus Partners LLC raised its holdings in BioLife Solutions by 34.4% in the second quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 42,265 shares in the last quarter. Quest Partners LLC purchased a new position in BioLife Solutions in the third quarter worth approximately $57,000. Finally, GAMMA Investing LLC grew its holdings in BioLife Solutions by 29.4% during the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock worth $83,000 after acquiring an additional 748 shares in the last quarter. Hedge funds and other institutional investors own 93.24% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on BLFS. Northland Securities upped their price target on BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. HC Wainwright dropped their price target on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a research report on Monday. TD Cowen boosted their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Finally, Craig Hallum increased their price objective on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $27.50.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.